Full antigenic signature capture
Imvax’s Goldspire™ platform exposes the full antigenic signature of a patient’s tumor to the immune system, providing an opportunity for a broader anti-tumor effect compared with single antigen-targeting therapies.
Our Science: The Goldspire™ Immunotherapy Platform
Harnessing the full antigen signature of solid tumors
Informed by decades of research, Imvax’s platform elegantly turns the complexity of a solid tumor against itself by capturing its complete antigenic signature and converting it into a highly immunostimulatory ‘training program’. This is designed to deliver both innate and adaptive immune stimulation to overcome the challenges of solid tumors’ variability and ability to suppress the immune system.
Our Goldspire™ platform
Imvax’s Goldspire™ platform is a personalized, whole tumor-derived, cell-based autologous immunotherapy that delivers a full tumor antigen payload to patients by combining patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against insulin-like growth factor type 1 receptor (IGF-1R). This combination is loaded into implantable, proprietary biodiffusion chambers (BDCs). Our platform is designed to be incorporated into the standard of care. In the graphic below, click into the two major steps unique to Imvax’s platform to learn more. Click here for a detailed downloadable summary of Goldspire's mechanism.
Patient admitted to hospital
Patient leaves hospital
Standard of care proceeds
Personalized Tumor Processing
After surgical removal and transfer to Imvax’s state-of-the-art manufacturing facility in Philadelphia, PA, patient tumor samples undergo rapid tissue processing (i.e., less than 24 hours). Imvax incubates a patient’s tumor cells with antisense and then places the cells in BDCs. These are irradiated with a low dose of radiation before being returned to the hospital for implantation in the patient.
Immune system training
The small biodiffusion chambers (BDCs) are loaded with the patient’s tumor cells (with their full antigen signature) and antisense molecule (IMV-001) to create a personalized combination product that is implanted in the abdomen for approximately 48 hours. During this time, the tumor cells inside the BDCs undergo immunogenic cell death (ICD). ICD causes the release of the full antigenic signature, which diffuses out of the BDC into the patient. In parallel, IMV-001 can downregulate the expression of IGF1R, a cell growth controller commonly overexpressed in tumors. This downregulation may also contribute to tumor cell death.
Data from Imvax’s preclinical studies suggest that the antigens and other immunostimulatory factors released from the BDCs stimulate nearby immune cells. These cells then travel to local lymph nodes to induce long-term adaptive immune responses against remaining tumor tissue in the body.
Unique advantages of the Goldspire™ platform against solid tumors
Broad spectrum immune activation
Imvax’s Goldspire™ platform delivers immunotherapy that is personalized to a patient’s entire unique tumor and incorporates mechanisms that stimulate both the innate and adaptive immune system. This broad-spectrum effect, when used in combination, also may enhance the effects of other immunotherapies.
No ‘off-target’ effects
Imvax’s Goldspire™ platform trains the immune system to comprehensively recognize the full antigenic signature of a patient’s unique tumor. Because the immune system ignores a patient’s own antigens, Imvax’s approach should avoid immune responses not directed to the tumor itself.
Less than 24-hour tissue processing
Imvax’s Goldspire™ platform uses a rapid tumor tissue processing technology to prepare the proprietary BDCs for implantation. By contrast, many emerging therapies targeting one or a small number of antigens require complex manufacturing procedures, such as gene editing and cell expansions, that can take several weeks.
Integrated into the ‘standard of care’
Imvax’s Goldspire™ platform can fit within the existing standard of care for patients with resectable solid tumors. Within days of tumor resection surgery, Imvax processes the tumor cells and the BDCs are then implanted in the patient and explanted 48-hours later. The patient’s immune system training begins immediately, after which they can continue with traditional standard-of-care therapies.
Research, Development, and Manufacturing Overview
Publications
Sort By
Perez-Olle, R. et al. “Additional Results From a Phase 1b Study of IGV-001 in Patients With Newly Diagnosed Glioblastoma” Presented at SNO 2023.
Lee, I. et al. “A randomized, multicenter, double-blind, phase 2b study of IGV-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients” Presented at SNO 2023.
Lee, I. et al. “Trial in progress: a randomized, multicenter, double-blind, placebo-controlled, phase 2b study to assess the safety and efficacy of IGV-001, an autologous cell immunotherapy with antisense oligonucleotide (IMV-001) targeting IGF-1R, in newly diagnosed patients with glioblastoma” Presented at SNO/ASCO 2023.
Cultura, C. et al. “A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.” Journal for ImmunoTherapy of Cancer, Aug. 2023. DOI 10.1136/jitc-2023-006880